Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Niagen Bioscience (NAGE) Consolidated Net Income: 2010-2025

Historic Consolidated Net Income for Niagen Bioscience (NAGE) over the last 14 years, with Sep 2025 value amounting to $4.6 million.

  • Niagen Bioscience's Consolidated Net Income rose 143.77% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.4 million, marking a year-over-year increase of 1275.69%. This contributed to the annual value of $8.6 million for FY2024, which is 273.15% up from last year.
  • As of Q3 2025, Niagen Bioscience's Consolidated Net Income stood at $4.6 million, which was up 26.85% from $3.6 million recorded in Q2 2025.
  • Over the past 5 years, Niagen Bioscience's Consolidated Net Income peaked at $7.2 million during Q4 2024, and registered a low of -$8.9 million during Q3 2021.
  • For the 3-year period, Niagen Bioscience's Consolidated Net Income averaged around $1.5 million, with its median value being $114,000 (2023).
  • In the last 5 years, Niagen Bioscience's Consolidated Net Income slumped by 110.11% in 2021 and then skyrocketed by 24,160.00% in 2025.
  • Niagen Bioscience's Consolidated Net Income (Quarterly) stood at -$5.3 million in 2021, then surged by 72.88% to -$1.4 million in 2022, then skyrocketed by 107.89% to $114,000 in 2023, then spiked by 6,197.37% to $7.2 million in 2024, then surged by 143.77% to $4.6 million in 2025.
  • Its Consolidated Net Income stands at $4.6 million for Q3 2025, versus $3.6 million for Q2 2025 and $5.1 million for Q1 2025.